Table 2.

Cytokine-induced changes in transcription factor mRNA levels

Probe set ID	Gene name	GenBank no.	Microarray	Quantitative PCR
201565_s_at	ID2: inhibitor of DNA binding 2, dominant-negative helix-loop-helix protein	BC030639	(+) 3.1 ± 0.7	(+) 2.3 ± 1.2
201694_s_at	EGR1: early growth response 1	X52541	(+) 3.5 ± 1.7	(+) 3.8 ± 2.6
201862_s_at	LRRFIP1: leucine-rich repeat (in FLII) interacting protein 1	AJ223075	(+) 2.9 ± 0.6	(+) 2.1 ± 0.3
202370_s_at	CBFB: core-binding factor, beta subunit	BC018509	(+) 4.7 ± 0.5	(+) 2.5 ± 0.2
203617_x_at	ELK1: ELK1, member of ETS oncogene family	BC056150	(+) 2.7 ± 1.2	(+) 3.3 ± 0.4
204959_at	MNDA: myeloid cell nuclear differentiation antigen	BC032319	(+) 36.0 ± 18.7	ND
215933_s_at	HHEX: hematopoietically expressed homeobox	BC015110	(+) 4.4 ± 1.2	(+) 3.0 ± 1.2
219498_s_at	BCL11A: B-cell CTT/lymphoma 11A (zinc finger protein)	AJ404611	(−) 2.2 ± 0.3	(−) 1.7 ± 0.2
223865_at	SOX-6: SRY (sex determining region Y)-box 6	BC047064	(−) 7.0 ± 4.2	(−) 5.3 ± 1.5
227798_at	SMAD1: SMAD family member 1	BC001878	(−) 2.6 ± 0.8	(−) 2.3 ± 0.5
228381_at	ATF7IP2: activating transcription factor 7 interacting protein 2	BC033891	(+) 3.1 ± 0.5	(+) 2.7 ± 0.4
229657_at	THRB: thyroid hormone receptor, beta (erythroblastic leukemia viral [v-erb-a] oncogene homolog 2, avian)	M26747	(−) 2.7 ± 0.7	(−) 4.4 ± 1.5
36711_at	MAFF: v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian)	AJ010857	(+) 5.3 ± 1.6	(+) 4.5 ± 3.7

Thirteen genes that were identified to be differentially expressed by the microarray analysis (15 separate donor-matched) were studied using quantitative real-time RT-PCR to verify. Quantitative PCR was performed in RNA from day 7 cultured erythroblasts (3 separate donor-matched). Average expression fold change compared in high-HbF versus low-HbF culture conditions is shown with SD.

(−) indicates down-regulated in high-HbF condition; (+), up-regulated in high-HbF condition; and ND, not determined.